Triglycerides: A Sensitizer but Not a Trigger for Hypertriglyceridemic Acute Pancreatitis
- PMID: 38609542
- DOI: 10.1007/s10620-024-08412-x
Triglycerides: A Sensitizer but Not a Trigger for Hypertriglyceridemic Acute Pancreatitis
Abstract
Background: The incidence of hypertriglyceridemic acute pancreatitis (HTG-AP) is increasing. Although the guideline defines the diagnostic criteria as triglyceride (TG) greater than 11.3 mmol/L, there is actually no specific threshold. Many people with hypertriglyceridemia (HTG) or obvious chyloid blood do not develop acute pancreatitis (AP).
Aims: To explore the role of HTG in the pathogenesis of AP.
Methods: Thirty-six male SD rats were randomly assigned into normal control, AP, HTG, HTG-AP, low-dose fenofibrate and high-dose fenofibrate groups. Serum indices and cytokine levels in serum, and pathological changes in pancreatic tissues were observed. The expression levels of TLR4 and NF-κBp65 in pancreatic tissues were detected by immunohistochemistry and Western blot.
Results: In normal rats, HTG alone did not induce AP. However, after establishing the HTG-AP model with Poloxam 407 and L-arginine, serum-free fatty acid and TG levels were positively correlated with the levels of lipase, amylase, IL-1β, IL-6, pancreatic inflammation scores, and the expressions of TLR4 and NF-κBp65 (all P < 0.001). Expressions of TLR4 and NF-κBp65 were significantly increased in the pancreatic tissues of HTG-AP rats. Fenofibrate effectively decreased TG levels in HTG-AP rats and reduced the expression of TLR4 and NF-κBp65 (all P < 0.001).
Conclusions: HTG does not directly cause AP, but rather increases the susceptibility to AP or aggravates the inflammatory response. It is more like a sensitizer of inflammation rather than an activator.
Keywords: Acute pancreatitis; Hypertriglyceridemia; Hypertriglyceridemic acute pancreatitis; NF-κBp65; TLR4.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Incidence and clinical characteristics of hypertriglyceridemic acute pancreatitis: A retrospective single-center study.World J Gastroenterol. 2022 Aug 7;28(29):3946-3959. doi: 10.3748/wjg.v28.i29.3946. World J Gastroenterol. 2022. PMID: 36157550 Free PMC article.
-
FIBRINOGEN-LIKE PROTEIN 2 PROTECTS THE AGGRAVATION OF HYPERTRIGLYCERIDEMIA ON THE SEVERITY OF HYPERTRIGLYCERIDEMIA ACUTE PANCREATITIS BY REGULATING MACROPHAGES.Shock. 2025 Feb 1;63(2):327-337. doi: 10.1097/SHK.0000000000002503. Epub 2024 Nov 4. Shock. 2025. PMID: 39527492
-
Clinical Analysis of Atorvastatin Calcium, Fenofibrate, and Acipimox in the Treatment of Hypertriglyceridemia-induced Acute Pancreatitis.Altern Ther Health Med. 2024 Dec;30(12):200-207. Altern Ther Health Med. 2024. PMID: 38518139
-
Current knowledge of hypertriglyceridemic pancreatitis.Eur J Intern Med. 2014 Oct;25(8):689-94. doi: 10.1016/j.ejim.2014.08.008. Epub 2014 Sep 27. Eur J Intern Med. 2014. PMID: 25269432 Review.
-
Mechanisms linking hypertriglyceridemia to acute pancreatitis.Acta Physiol (Oxf). 2023 Mar;237(3):e13916. doi: 10.1111/apha.13916. Epub 2023 Jan 13. Acta Physiol (Oxf). 2023. PMID: 36599412 Review.
References
-
- Whitcomb DC. Clinical practice. Acute pancreatitis. N Engl J Med. 2006;354:2142–2150. - PubMed
-
- Matta B, Gougol A, Gao X, et al. Worldwide Variations in Demographics, Management, and Outcomes of Acute Pancreatitis. Clin Gastroenterol Hepatol. 2019 .
-
- Adiamah A, Psaltis E, Crook M, Lobo DN. A systematic review of the epidemiology, pathophysiology and current management of hyperlipidaemic pancreatitis. Clin Nutr. 2018. 37: 1810–1822.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous